Wednesday, August 24, 2016

A Call For Mylan CEO Heather Bresch To Reduce EpiPen Price And Resign; Huffington Post, 8/24/16

Andrew B. Palumbo, Huffington Post; A Call For Mylan CEO Heather Bresch To Reduce EpiPen Price And Resign:
"The EpiPen’s only legitimate U.S. competitor, Sanofi’s Auvi-Q, was voluntarily recalled nationwide in October 2015 after dangerous issues of inaccurate dosage delivery arose that could include a failure to administer the life-saving epinephrine. Immediately, millions of families with life threatening allergies turned to Mylan to secure EpiPens.
The result was a de facto monopoly for Mylan. Since Mylan secured the rights to the EpiPen in 2007, they have steadily raised prices over 460 percent (from an average wholesale of $56.64 to $317.82). CEO Heather Bresch – daughter of U.S. Senator Joe Manchin of West Virginia – increased her own compensation by more than 670 percent from $2.5M to $18.9M during the same time.
With no other competitors in the United States, families are forced to pay extortionate rates for what amounts to $1.00 worth of epinephrine per EpiPen."

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.